FDA Brief

Warning letters Drugs

FDA warning letter to

Gram Peptides

High riskIssued Mar 31Posted Apr 7Center for Drug Evaluation and Research (CDER)

Gram Peptides sold unapproved injectable peptide drugs and bacteriostatic water online as new drugs, FDA says.

What happened

FDA reviewed Gram Peptides' website from January to March 2026 and found it offered Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection for sale in the United States. FDA said the products are unapproved new drugs and that website claims showed they were intended for human use, despite "Research Use Only" statements.

What FDA found

  1. Gram Peptides offered Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection for sale in the United States without FDA-approved applications, making them unapproved new drugs.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. Introducing or delivering these unapproved new drugs into interstate commerce violates the FD&C Act.

    Sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  3. The products are "new drugs" because they are not generally recognized as safe and effective for the uses described in their labeling.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  4. Website labeling showed the products were intended for human use as drugs, despite statements limiting them to research use.

    21 CFR 201.128
  5. Bacteriostatic Water for Injection was sold alongside injectable peptide products, showing it was intended for use in injection.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

FDA asks Gram Peptides to notify FDA in writing within 15 working days of receipt about the specific steps taken to correct the violations and prevent recurrence, including related documentation. If the company cannot complete corrections in that time, it must state why and when it will finish.

Who should pay attention

  • online peptide and supplement sellers
  • companies selling injectable research chemicals
  • clinics or buyers sourcing peptides online

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk